Barriers & Challenges

The evidence, policy, workforce, infrastructure, stigma, and system constraints that can slow implementation after approval.

The barriers to psychedelic therapy access are not one problem. Evidence gaps, controlled-drug rules, workforce limits, delivery cost, payer uncertainty, public trust, and political risk all interact.

A country can have promising research and still lack trained providers, reimbursed treatment settings, appropriate referral routes, or enough confidence from payers and clinicians.

Use this section to identify which constraints are most likely to block implementation and which ones need to be addressed before launch planning becomes credible.

Guides and tools

2 Apr 2026Reimbursement Report

Challenges and Barriers to Reimbursement

Why psychedelic therapies can be hard to assess, pay for, and deliver even when clinical results are promising.

Barriers & Challenges

Guides and tools

Challenges and Barriers to Reimbursement

Further reading

Company

Product

Legal